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The antipneumococcic mouse-protective activity of sera from human sub- 
jects  before  and  after  inoculation with  pneumococci  or  type-specific poly- 
saccharides was measured in this study and compared with  the amounts of 
precipitable antibody nitrogen in the  same sera.  The measurements of the 
precipitable antibody nitrogen have been reported in the preceding paper (1). 
The mouse protection tests add knowledge of the in vivo potency of the anti- 
bodies to the evidence of their activity in vitro, and they indicate that a com- 
parison with measurements of mouse-protective antibodies should be feasible 
in other  similar studies. 
Methods and Materials 
Tecknic.--Mouse protection tests were carried out by the method used by the New York 
City Health Department, Bureau of Laboratories,  for standardization  of therapeutic  anti- 
pneumococcic sera with  the exception that the small volumes of sera available permitted 
few duplicate tests, each with ten mice per serum dilution. 
The Type I and Type II cultures were passed through mice from one to five times weeHy 
and stored between passages at 10°C. in beef heart phosphate  broth containing 3 per cent 
horse blood.  For the test an 18 hour blood broth culture of the heart blood of a mouse 
injected 5 hours previously was adjusted turbidimetrically  so that 10  -8 ml. in a volume of 
0.5 ml. contained about 2 microorganisms (1 K.L.D.).  All culture dilutions were made with 
beef heart phosphate broth.  The test dose of culture for each type was 10  -a ml. contained 
in 0.5 ml. of broth, approximately 100,000 M.L.D.  This dose of culture is protected against 
by 1/10 unit of serum (2).  As controls of the virulence of the culture poured blood agar 
plates were made of the 1G  -s, 10  -7, 5 X 10  -8, 2 X  10  -s, 10  -s, and 5 X 10  -8 ml. culture dilu- 
tions in 0.5 ml. volumes and one mouse was injected intraperitoneally with 0.5 ml. of broth 
and 0.5 ml. of each of these culture dilutions at the beginning and at the end of each test. 
Control mice which received two or more pneumococci as determined by plate counts died 
within 72 hours.  The sera were diluted in 0.85 per cent sodium chloride solution so that the 
desired amounts were contained in 0.5 ml. 
As a control serum the National Institute of Health bivalent Type I and Type II horse 
serum P-11 was included in each test.  Monovalent Type I or Type II hyperimmune rabbit 
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serums were also included in a  number of the tests.  Mice were injected intraperitoneally 
with 0.5 ml. of the test culture dilution and 0.5 mi. of the serum dilution drawn into a  1 ml. 
insulin type syringe.  Up to ten mice were injected with each serum dilution, the number 
of mice being determined by the amount of serum available.  All injections were completed 
within 60 minutes of the time dilution of the culture was begun.  The mice were inspected 
twice daily for. 120 hours.  Sickness and deaths were recorded and cultures on blood agar 
plates were made from the heart blood of sufficient mice to determine that deaths were due 
to  uncomplicated pneumococcns septicemia.  Although the  test was  considered complete 
at 96 hours, the occurrence of a large number of deaths after this time was taken into account 
in planning second tests of sera.  The majority of the mice used were the CFW strain.  Their 
weights ranged from 15 to 19 gm.  At the conclusion of each test the unit value of each serum 
in comparison with the control serum was calculated from the deaths and survivals at 96 
hours by the S0 per cent endpoint method of Reed and Muench as adapted by Goodner and 
Horsfall (3).  The established values of control serum P-11 are Type It 300 units per ml.; 
Type II, 150 units per ml. 
From most of the subjects less than 5 mh of serum was received from each bleeding.  As 
0.5 mh of a serum containing 0.2 unit per mi. or 0.1 mh of a serum containing 1 unit per ml. 
is necessary for protection against the test dose of culture, it can be seen that duplicate 
tests using ten mice for each serum dilution were not possible with those sera which were in 
this range of unit potencies.  Only the results of tests in which 50 per cent endpoints could 
be calculated are reported below. 
The results of repeated tests of National Institute of Health control serum, hyperimmune 
rabbit sera, and those human sera in which two tests were carried out with ten mice per serum 
dilution showed satisfactory agreement.  In thirteen Type I  tests, the 50 per cent survival 
endpoint of control serum P-11 averaged 440 units per ml. with a range of from 320 to 650 
units per ml.; in thirteen Type II tests with the same serum, the average was 260 units per 
mi. with a  range of from 115 to 380 units per mh  Type I  hyperimmune rabbit serum, lot 
3-745, contained 1.44 rag. specifically precipitable nitrogen per mh  In seven Type I  mouse 
protection tests of this serum in comparison with P-11 the average was 2,180 units per ml., 
with a range of from 1,650 to 2,480 units per mh  The ratio,  mouse protection units to milli- 
grams of antibody nitrogen, averaged 1,500 with  a  range of from 1,145  to  1,720  units per 
rag.  Type II hyperimmune rabbit serum, lot 579RS D39,  contained 0.94 nag. specifically 
predpitable nitrogen per mh  In six Type II  mouse protection tests of this serum in com- 
parison with P-11, the average value was 540 units per mi. with a range of from 276 to 1,030 
units per nil.  The ratio, mouse protection units to milligrams of antibody nitrogen, averaged 
580 with a range of from 294 to 1,096 units per rag.  Duplicate  mouse protection tests with 
ten mice per serum dilution were not completed for any of the human sera tested against 
Type I.  Duplicate tests with ten mice per  dilution were completed for eight human sera 
tested against Type II organisms.  The  greatest variation in results for any one of these 
eight sera occurred with serum 53-6 which titered 19 and 14 units per mi. respectively in two 
tests. 
Sub]ects.--The sera  studied were  representative  samples from  the immunized subjects 
described in the preceding paper, and were selected chiefly because the volumes of the serum 
samples were larger. 
Group 1 received two intravenous injections, 3 days apart, of a total of 10 billion each of 
the Type I and Type II pneumococci containing 0.03 rag.  and 0.04 rag. respectively of Type 
I and Type II specific polysaccharides (S I and S II).  Group 2  received two intracutaneous 
injections 5 days apart of the washed copper precipitate from a solution of S I and S II.  It 
is doubtful whether the entire amounts intended, 0.03 mg. S I  and 0.04 rag. S II for com- 
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tended to  stick  in  the  syringes.  Group  3 received  two  intracutaneous  injections  6  days 
apart of polysaccharide solution, 0.05 rag. each of S I and S II.  Group 4 received the same 
dose as group III but by two subcutaneous  injections 8 days apart.  Group 5 received 0.06 
nag. each of S I, S II, and S V subcutaneously  in two doses 3 days apart. 
TABLE I 
Type I Antibody Nitrogen, Mouse-Protective Titer, and the Ratio, Mouse Protection: Antibody 
Nitrogen in tke Sera of Immunized Subjects 
Antibody nitrogen 
Micrograms per 4 ml. (1)  Mouse-protective titer 
Group  Subject  Bleeding  No.  I  i Ratio, Unitl 
per ml.:  No. of mice  An~-C  Anti-I  Units  per ml,  antibody  N  per dilution 
rag. per ml. 
I  10  2  15  0.17  45  I to 3 
15  I  82  4.0  195  St  of  0 
3  64  4.3  269  10 
5  60  3.8  253  9tolO 
7  28  44  3.1  282  5 
16  2  25  0.8  128  3 
5  25  2.1  336  I to 3 
17  7  13  11  0.5  182  3to5 
2  29  2  40  4.7  470  10 
3  31  3.3  426  10 
4  30  1.5  200  I0 
5  25  27  0.6  89  10 
6  24  14  0.8  228  5 
31  2  19  0.49  103  I to 2 
3  7  0.14  80  3 
4  12  0.2  i  67  1 to 3 
3  39  1  20  0.35  70  lto2 
2  22  0.15  27  3 
43  1  37  0.44  48  1 to 3 
4  54  1  16  2.2  550  3 
2  28  1.25  178  3 
3  41  23  1.2  209  5 
56  1  86  6.2  288  8 
3  149  2.3  62  10 
59  1  45  0.53  47  2 to 3 
5  78  4  18  46  0.8  70  5 
5  37  41  0.4  39  10 
RESULTS 
The results of tests  of post.inoculation sera for Type T protective antibody 
are  shown  in  Table  I,  and  for  Type  II  antibody  are  shown  in  Table  II. 
Twenty-seven samples from twelve subjects were tested for Type I  protection, 
and  thirty-one  samples  from fourteen subjects were tested  for Type  II pro- 
tection.  Only  two  samples  were  tested  for both  Types  I  and  II  and  they 324  TITERS  OF  SERA  AFTER  INyECTION  0]~,  PNEUMOCOCCI 
TABLE II 
Type 1I Antibody Nitrogen, Mouse-Protectire Titer, and tke Ratio, Mouse Protection: Antibody 
Nitrogen in the Sera of Immunized Subjects 
Group  Subject  Bleeding 
No. 
Antibody nitrogen (I):  Mouse protective titer 
micrograms per 4 ml. I 
Ratio.  Units 
Anti-C  Anti-II  Units per  per ml.: 
ml.  antibody N 
n~. per ml. 
1  9  3  102  4.9 
4  99  4.5 
13  4  15  1.5 
17  2  152  8.2 
3  136  8.9 
7  55  3.65 
2.9 
19  1  24  26.1 
2  144  11.5 
7  52  2.7 
8  43  3.1 
2  24  4  31  0.42 
30  2  7  0.6 
3  9  0.24 
6  4  0.6 
3  38  1  121  6.2 
2  142  14.4 
19.0 
4  137  27.0 
48  1  42  1.3 
4  39  2.9 
4  52  1  58  1.3 
4  48  0.7 
0.9 
53  1  247  38.5 
3  251  26.0 
32.0 
4  231  23.0 
27.0 
,5  140  23.1 
18.8 
6  155  19.0 
14.0 
5  62  4  45  O. 5 
5  25  0.3 
74  5  48  3.4 
78  4  25  O. 5 
0.5 
82  4  44  0.6 
192 
182 
400 
216 
262 
265 
211' 
No. of mice [mr 
dilution 
4350 
319 
208 
288 
54 
343 
107 
600 
205 
406 
535* 
788 
124 
297 
9O 
5~} Av. 
7  67* 
623 
414~ 
510~ 
398~ 
468 
537~ 
44 
48 
283 
80 
80 
54 
i0 
i0 
3 to I0 
I0 
I0 
5 
5 (repeated) 
7to I0 
I0 
8 to I0 
7 to I0 
3 
3 
3 
5 
8to 10 
10 
10 (repeated) 
5 
I0 
5 
10 
5 
5 (repeated) 
I0 
Av.  I0 
462*  10 (repeated) 
Av.  10 
433*  10 (repeated) 
Av.  10 
599*  10 (repeated) 
Av.  10 
426*  10 (repeated) 
5 to 10 
5 to I0 
10 
5 
5 (repeated) 
I0 
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appear in both tabulations, namely bleeding  7 of subject 17  and bleeding  4 
of subject 78. 
All the subjects tested had, with one exception, protective antibodies in at 
least one postinoculation sample  sufficient  to protect against the 0.001 ml. 
test dose of culture containing 100,000 ~.L.D.  In most cases the serum could 
be diluted and still protect against the test dose.  In general,  Type I  anti- 
bodies were lower in titer than Type II, corresponding  to the lesser amounts 
of precipitable  antibody nitrogen found for Type I as compared with Type II. 
There was a  tendency for the mouse-protective  titer to be lower in the later 
bleedings from the same subjects,  just as the quantities of antibody nitrogen 
tended to be lower. 
The-number of subjects  in the groups  receiving different antigens was too 
small to justify comparisons  of antigenic potency with respect  to the mouse- 
protective titer produced by individual antigens.  Variations in precipitable 
anti-C antibody or repeated inoculations  with antigens had no pronounced 
effect on mouse-protective  titer or the ratio of mouse-protective  titer to anti- 
body nitrogen. 
Samples  of sera taken before inoculation from eleven subjects were tested 
for mouse-protective  activity using amounts of  culture smaller  than  0.001 
ml.  Eight, from subjects 10,  15,  16, 31, 43, 54, 56, and 59, were tested for 
Type I antibodies, and three, from subjects 9, 48, and 53, were tested for Type 
II antibodies.  Amounts of 0.1 ml. of serum were given to each of four mice 
with small doses of culture: 10  -8,  10-  ~, 10  -6,  10- ~ ml. or 100,000; 1,000;  100; 
and 10 ~r.L.D. respectively.  The sera  of two subjects showed mouse-protec- 
tive activity, No. 56 against Type I, No. 9 against Type II, both protecting 
against a maximum of 10  -5 ml. containing 10,000 ~r.LD.  Neither was potent 
enough to protect against 0.001 ml. containing 100,000 ~.LD., the test dose of 
culture used for the determination of units.  Type I  precipitable  antibody 
nitrogen, 11  micrograms  per 4 ml., was found in the serum from subject 56. 
Neither Type I nor Type II precipitable  antibody nitrogen was found in the 
sera of five other subjects that showed no mouse protection.  Pre-immuniza- 
tion sera from the remaining five subjects were not examined by the method, 
used later, which was sufficiently accurate to measure such small amounts of 
precipitable antibody nitrogen (1). 
In order to find out whether a regular relationship existed in these low titer 
sera between  mouse protection units and precipitable  antibody nitrogen,  the 
ratios of the two values were calculated.  The ratio varied widely from 27 to 
550 for Type I, and from 44  to 4,350 for Type II.  When the results  were 
listed in the order of the number of mouse protection units, there was a marked 
tendency for lower ratios to be associated with lower mouse-protective  values. 
For both Type I and Type II the average ratio (Table III) was the lowest for 
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TABLE III 
Rdatiouship  of Mouse  Protection to  the  Ratio,  Mouse  Protection:  Antibody  Nitrogea 
Antibody nitrogen  Ratio  Mouse-protective titer  micrograms  per 4 ml. 
Kind  of serum 
Type 1 human 
Type 1  rabbit 
Range of observa- 
tions 
Units per ml. 
0to 1.0 
I.I to5.0 
More than  5.0 
1650 to 2480 
No.  of s  era 
14 
12 
1 
Range of 
observations 
7 to46 
16 to 149 
86 
5750 
hyperimmune 
lot 3-745 
Type 2 human 
Type 2 rabbit 
hyperimmune 
lot  579 
0 to 1.0 
1.1 to  5.0 
5.1 to  39 
276 to 1030 
Examined 
7 times 
9 
10 
12 
1 
Examined 
6 times 
4  to 48 
15 to 102 
24 to 251 
3760 
Average 
24 
49 
86 
26 
55 
157 
Mouse protection units pel 
ml.: antibody nitrogen mg 
per ml. 
Range of observa- Averagl 
tious 
27 to 228  87 
62 to 550  286 
288  288 
1145 to 1720  1514 
44 to 6O0  155 
90 to 40O  228 
205 to 4350  768 
294to1096  i  579 
TABLE  IV 
E.~ect of Normal Serum on the Mouse-Protective Titer of Hyperimmune  Rabb~ Anlipneumo- 
coccic Serum 
Antiserum 
Type 1 
Lot 3-745 
First test 
Type 1 
Lot 3-745 
Second test 
Diluent 
0.85 per cent NaC1 
Normal human AA 
232 
Normal rabbit 1 
0.85 per cent NaCI 
Normal human AA 
233 
Normal human AA 
233* 
Normal rabbit 2 
Normal rabbit 2* 
Units of mouse  protection 
per rot. 
2570 
805 
2180 
930 
620 
670 
905 
1010 
Ratio: 
Mouse-protective 
units per ml. 
Antibody nitro- 
gen rag. per mL 
1785 
559 
1514 
646 
431 
465 
628 
701 
* Duplicate test carried out at same time. 
1  to  5  units  of  protection  per  ml.  Only  one  serum  was  tested  for  Type  I 
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protective activity per ml. were found in twelve sera ranging  from 6.2 to 38.5 
units per ml. and the ratio was 770, even higher than that found in the hyper- 
immune rabbit  serum. 
The  possibility  that  the  relatively  large  amounts  of  serum  components 
other than antibody contained in serum  of low potency interfered with  the 
protective action of the antibody was explored by measuring the mouse-pro- 
tective  titer  of hyperimmune  rabbit  antipneumococcic  serum  with  normal 
human sera as a diluent, and comparing the titer with that of the same hyper- 
immune rabbit sera diluted with normal rabbit serum and with saline (Table 
IV).  Normal  human and normal rabbit sera were chosen that had  no pro- 
tective action in the amounts used in the test.  Relatively large amounts of 
normal human  serum  as  diluent  caused  a  consistent lowering of the  values 
resulting from the titration, but these ratios were not as low as the ratios of 
mouse protection to antibody nitrogen described above for sera titering less 
than one unit per ml. 
DISCUSSION 
Because of insufficient amounts of serum only part of the mouse protection 
tests were carried out with the full number of mice and with repetitions of the 
tests as prescribed for the titration of therapeutic sera.  Agreement was good in 
the findings with hyperimmune sera examined repeatedly and in the human sera 
in which determinations were repeated using 10 mice per dilution.  The results 
can therefore be considered reliable.  All of  the  subjects  tested except  one 
were shown  to have substantial  amounts  of mouse-protective activity  after 
immunization and the results for eleven subjects showed the development or 
increase in titer of mouse-protective antibody after immunization. 
The low ratio of units  of mouse protection per milliliter to milligrams of 
antibody nitrogen per milliliter in human  sera  of the lowest titer suggested 
that the precipitable antibody nitrogen when present in small amounts was of 
low potency.  The possibility that technical factors in the protection or pre- 
cipitation tests could have led to the same findings was also considered.  In- 
terference with  the protective activity of small amounts of antibody by the 
relatively large amounts of other serum components in weak human sera was 
studied by titering hyperimmune rabbit sera diluted in human sera as com- 
pared  with saline dilution (Table IV).  Dilution with  either of two different 
human  sera  reduced  the  mouse-protective activity  of  rabbit  hyperimmune 
sera, but the difference was not great enough to provide an explanation of the 
lowest ratios observed.  A potential error, due to the presence of non-specific 
precipitable substances tending to make the analyses too high, was also con- 
sidered.  Further studies of animal sera of low and high potency have been 
undertaken to clarify this question but they are not completed. 
Comparsion of the mouse-protective titers after immunization with the titers 
observed by others (4-6)  can be made by calculating the proportion of sub- 328  TITERS 0]~ SERA AFTER INJECTION OF PNEUMOCOCCI 
jects whose serum contained 1 unit of protection or more; i.e., 0.1 ml. amounts 
protected  mice against  100,000  ~.L.D.  of  the  same pneumococcic type.  In 
this study the proportion was 5 out of 12 for Type I and 9 out of 14 for Type II. 
Felton et al. studied mouse-protective fiters of human sera from large grouFs 
of  subjects  following  inoculations  with  pneumococcic  polysaccharides  and 
found a  somewhat smaller number containing one unit or more  as defined 
above.  In one study (4)  of 533  subjects who  received varying amounts  of 
antigen,  the sera  of  152  or 29  per cent protected against  100,000  M.L.D. of 
Type I, and the sera of 270 or 51 per cent protected similarly against Type II. 
In another study (5), in which relatively large amounts of antigen were used 
to inoculate 1,099 subjects, the sera of 260 or 24 per cent of the injected in- 
dividuals protected against 100,000 ~.L.D. of Type I  culture and the serum of 
440  or 40  per cent protected against a  similar amount of Type II culture. 
Other authors  (6)  administered smaller amounts of  antigens and had  even 
smaller numbers of subjects whose sera developed protection against 100,000 
Z~.L.D. or more of culture.  The data summarized do not show striking differ- 
ences betweeu postinoculation antibodies in the present studies, and those re- 
ported by others. 
CONCLUSIONS 
I. Sera of  human subjects immunized with pneumococci or their  type-spe- 
cific  polysaccharides showed type-specific  antibody by mouse protection  tests 
as well  as on determinations of the specifically  precipitable  nitrogen. 
2. The ratio,  m0use-protective units  to antibody nitrogen,  was less  in hu- 
man sera  of low potency than in more potent human or animal sera. 
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